United Health Products, Inc. (OTCQB:
UEEC) announced that it has received formal notification of
allowance of its patent application from the U.S. Patent Office for its
hemostatic gauze product, HemoStyp™, and that the patent will issue
shortly. The Company is also pursuing additional applications and
filings for its HemoStyp product line.
HemoStyp is an all-natural product comprised of regenerated oxidized
cellulose gauze which is specifically formulated to aid in the process
of hemostasis (clotting) when positioned on a cut or wound. Unlike the
other products in the wound care market, HemoStyp contains no
potentially harmful chemicals or animal byproducts and is
hypoallergenic. Once it has completed its task, it is easily removed by
dissolving it in water or saline solution. This method of removal
neither disturbs the clotted surface nor encourages re-bleeding.
Dr. Phillip Forman, CEO of United Health Products, stated that, "Now
that the Company has obtained full patent rights for HemoStyp, we look
forward to entering the next phase of sales and marketing with our
patented product."
The Company expects its first orders from the dental and medical markets
as it is now pursuing multiple markets for HemoStyp including the
medical, sports, dental, military, and veterinary sectors, each of which
represents a multimillion dollar market.
About United Health Products, Inc.
United Health Products, Inc. (UEEC) develops, manufactures, and markets
a patented hemostatic gauze, for the healthcare and wound care sectors.
The product, HemoStyp™, is derived from regenerated oxidized cellulose,
which is all natural, and designed to absorb exudate/drainage from
superficial wounds and helps control bleeding. UEEC is focused on
identifying new markets and applications for its product as well as
ramping up sales in its current markets. For more on United Health
Products, Inc. visit: www.unitedhealthproductsinc.com.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release may contain forward-looking information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements that include the words "believes,"
"expects," "anticipates" or similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of the Company to differ materially from those expressed or implied by
such forward-looking statements.
Copyright Business Wire 2013